Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition

被引:98
作者
Takei, M [1 ]
Fukuda, H [1 ]
Kishii, R [1 ]
Hosaka, M [1 ]
机构
[1] Kyorin Pharmaceut Co Ltd, Discovery Res Labs, Shimotsuga, Tochigi 3290114, Japan
关键词
D O I
10.1128/AAC.45.12.3544-3547.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The antibacterial activities and target inhibition of 15 quinolones against grlA and gyrA mutant strains were studied. The strains were obtained from wild-type Staphylococcus aureus MS5935 by selection with norfloxacin and nadifloxacin, respectively. The antibacterial activities of most quinolones against both mutant strains were lower than those against the wild-type strain. The ratios of MICs for the gyrA mutant strain to those for the grlA mutant strain (MIC ratio) varied from 0.125 to 4. The ratios of 50% inhibitory concentrations (IC50S) of quinolones against topoisomerase IV to those against DNA gyrase (IC50 ratios) also varied, from 0.177 to 5.52. A significant correlation between the MIC ratios and the IC50 ratios was observed (r = 0.919; P < 0.001). These results suggest that the antibacterial activities of quinolones against the wild-type strain are involved not only in topoisomerase W inhibition but also in DNA gyrase inhibition and that the target preference in the wild-type strain can be anticipated by the MIC ratios. Based on the MIC ratios, the quinolones were classified into three categories. Type I quinolones (norfloxacin, enoxacin, fleroxacin, ciprofloxacin, lomefloxacin, trovafloxacin, grepafloxacin, ofloxacin, and levofloxacin) had MIC ratios of < 1, type II quinolones (sparfloxacin and nadifloxacin) had MIC ratios of > 1, and type III quinolones (gatifloxacin, pazufloxacin, moxifloxacin, and clinafloxacin) had MIC ratios of 1. Type I and type II quinolones seem to prefer topoisomerase IV and DNA gyrase, respectively. Type III quinolones seem to target both enzymes at nearly the same level in bacterial cells (a phenomenon known as the dual-targeting property), and their IC50 ratios were approximately 2.
引用
收藏
页码:3544 / 3547
页数:4
相关论文
共 19 条
[11]   Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae [J].
Onodera, Y ;
Uchida, Y ;
Tanaka, M ;
Sato, K .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (04) :533-536
[12]   DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae [J].
Pan, XS ;
Fisher, LM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2810-2816
[13]   Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones [J].
Pan, XS ;
Fisher, LM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :471-474
[14]  
Shen LL, 1996, CURR PHARM DESIGN, V2, P195
[15]   Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases [J].
Takei, M ;
Fukuda, H ;
Yasue, T ;
Hosaka, M ;
Oomori, Y .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) :2678-2681
[16]   Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus [J].
Tanaka, M ;
Onodera, Y ;
Uchida, Y ;
Sato, K ;
Hayakawa, I .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2362-2366
[17]   ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae [J].
Varon, E ;
Janoir, C ;
Kitzis, MD ;
Gutmann, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :302-306
[18]  
Vogt K, 1995, Drugs, V49 Suppl 2, P266
[19]   Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus [J].
Yamagishi, JI ;
Kojima, T ;
Oyamada, Y ;
Fujimoto, K ;
Hattori, H ;
Nakamura, S ;
Inoue, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1157-1163